[Articles] Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019

Di |2024-04-17T00:30:02+02:00Aprile 17th, 2024|Categorie: Coronavirus Lancet|

Our detailed breakdown of DALYs associated with a comprehensive list of pathogens on a global, regional, and country level has revealed the magnitude of the problem and helps to indicate where research funding mismatch might exist. Given the disproport...

[Articles] Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019

Di |2024-04-17T00:30:02+02:00Aprile 17th, 2024|Categorie: Coronavirus Lancet|

Our detailed breakdown of DALYs associated with a comprehensive list of pathogens on a global, regional, and country level has revealed the magnitude of the problem and helps to indicate where research funding mismatch might exist. Given the disproport...

[Articles] Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021

Di |2024-04-16T00:30:02+02:00Aprile 16th, 2024|Categorie: Coronavirus Lancet|

Substantial progress has been made in reducing LRI mortality, but the burden remains high, especially in low-income and middle-income countries. During the COVID-19 pandemic, with its associated non-pharmaceutical interventions, global incident LRI cas...

[Articles] Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial

Di |2024-04-13T00:30:01+02:00Aprile 13th, 2024|Categorie: Coronavirus Lancet|

This first-in-human aerosol BCG controlled human infection model was sufficiently well tolerated. Further work will evaluate the utility of this model in assessing vaccine efficacy and identifying potential correlates of protection.

[Articles] An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial

Di |2024-04-12T00:30:01+02:00Aprile 12th, 2024|Categorie: Coronavirus Lancet|

CTH522, adjuvanted with CAF01 or CAF09b, is safe and immunogenic, with 85 μg CTH522-CAF01 inducing robust serum IgG binding titres. Intradermal vaccination conferred systemic IgG neutralisation breadth, and topical ocular administration increased ocula...

[Articles] Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial

Di |2024-04-11T00:30:01+02:00Aprile 11th, 2024|Categorie: Coronavirus Lancet|

The three dose groups of the candidate v7D vaccine exhibit similar humoral immunogenicity to the vOka vaccine and are well tolerated. These findings encourage further investigations on two-dose vaccination schedules, efficacy, and the potential safety ...

Torna in cima